Skip to main content

Table 3 Features of pazopanib-induced hypertension in the 20 patients in which it developed

From: Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development

Parameter Value Range
Change in systolic BP (mm Hg) 8.2 [−3.7-18.4] −54.6-26.3
Change in diastolic BP (mm Hg) 5.6 [0.4-11.4] −8.3-18.2
Maximal systolic BP (mm Hg) 167.5 [159.5-186.5] 148-195
Maximal diastolic BP (mm Hg) 96 [92-106.5] 80-112
Time until pazopanib-induced HTN (days) 24.5 [14.5-53.5] 7-641
Antihypertensive dose increased or new agent added 17 (85)  
No preexisting HTN 6 (30)  
Class of antihypertensive started or intensified
 ACEIs or ARBs 12 (46)  
 Beta-blockers 3 (12)  
 Calcium channel blockers 7 (27)  
 Diuretics 1 (4)  
 Others* 3 (12)  
  1. BP blood pressure, HTN hypertension, n number, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker
  2. Data presented as a number with percent (%) or median [1st quartile-3rd quartile]
  3. *Clonidine (n = 2) and hydralazine (n = 1)